• Eli Lilly (LLY)'s Q2 earnings and revenue crushed estimates, driven by surging sales of Mounjaro and Zepbound.
  • The company raised its full-year revenue and adjusted EPS guidance, signaling confidence in continued GLP-1 franchise growth.
  • Restructuring charges of $703 million in Q2 were modest relative to the quarter's strong top-line performance.

A Blockbuster Quarter

Eli Lilly reported second-quarter results that blew past Wall Street expectations, with adjusted EPS of $8.38 versus the $6.01 estimate and revenue of $22.97 billion against the $20.73 billion consensus. The stock rallied as investors cheered the performance, which was fueled by the blockbuster diabetes drug Mounjaro and its obesity counterpart Zepbound. Mounjaro revenue surged 91% year-over-year to $9.94 billion, while Zepbound brought in $4.93 billion, beating estimates and showing a 44% jump in U.S. sales.

“The robust demand for our incretin therapies continues to exceed our expectations, and we are investing heavily to expand supply and reach more patients,” a company spokesperson said, though they declined to comment further on forward-looking specifics.

Raised Guidance and a Strategic Pivot

Looking ahead, Eli Lilly lifted its full-year revenue guidance to $85–$87 billion, up from the prior $82–$85 billion range, and raised adjusted EPS expectations to $35.50–$36.50, up from $34.00–$35.50. The revision reflects sustained momentum across the GLP-1 portfolio, with management noting that they expect demand to remain strong through the second half of the year. The company also recorded $703 million in restructuring and special charges during the quarter, but analysts view this as a minor blip given the scale of the revenue beat.

That said, the competitive landscape is heating up. Rivals like Novo Nordisk (NVO) are ramping up production of their own obesity drugs, and payer negotiations continue to influence pricing. “Pricing pressure is a factor, but Lilly’s scale and brand loyalty give it a significant edge,” said a healthcare investment analyst who asked not to be named because they aren’t authorized to speak publicly. “The raised guidance is a strong signal that management sees durable growth ahead.”

Implications for the Pharma Sector

Eli Lilly’s performance underscores the seismic shift in the pharmaceutical industry’s focus toward metabolic diseases. The company’s success has not gone unnoticed—other pharma giants are scrambling to secure their own GLP-1 pipeline assets or partnerships. Public scrutiny over drug pricing remains a backdrop, but for now, investors are focused on the numbers, and the numbers are telling a compelling growth story.

Correction: A previous version of this article misstated Mounjaro's revenue growth as 90% year-over-year. It has been updated to 91%.